GPR17 polyclonal antibody, anti-human, mouse, rat
€0.00
In stock
SKU
BT-AP03713
Catalog Number: BT-AP03713
Size(s): 20μL, 50μL, 100μL
Isotype: Rabbit IgG
Reactivity: human, mouse, rat
Application(s): WB, IF, ELISA
Datasheet
Request Information
Size(s): 20μL, 50μL, 100μL
Isotype: Rabbit IgG
Reactivity: human, mouse, rat
Application(s): WB, IF, ELISA
Datasheet
Request Information
Background:
Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia.
Research Area: Neuroscience
Synonyms: GPR17, Uracil nucleotide/cysteinyl leukotriene receptor, UDP/CysLT receptor, G-protein coupled receptor 17, P2Y-like receptor, R12
Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Concentration: 1 mg/ml
Storage:
-20°C for 1 year
Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia.
Research Area: Neuroscience
Synonyms: GPR17, Uracil nucleotide/cysteinyl leukotriene receptor, UDP/CysLT receptor, G-protein coupled receptor 17, P2Y-like receptor, R12
Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Concentration: 1 mg/ml
Storage:
-20°C for 1 year
| Is Featured? | No |
|---|
Write Your Own Review